- Home
- SD vs SVRA Comparison
SD vs SVRA Comparison
Compare SD & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SD
- SVRA
- Stock Information
- Founded
- SD 2006
- SVRA N/A
- Country
- SD United States
- SVRA United States
- Employees
- SD N/A
- SVRA N/A
- Industry
- SD Oil & Gas Production
- SVRA Biotechnology: Pharmaceutical Preparations
- Sector
- SD Energy
- SVRA Health Care
- Exchange
- SD Nasdaq
- SVRA Nasdaq
- Market Cap
- SD 465.2M
- SVRA 446.2M
- IPO Year
- SD 2007
- SVRA N/A
- Fundamental
- Price
- SD $11.19
- SVRA $2.72
- Analyst Decision
- SD
- SVRA Buy
- Analyst Count
- SD 0
- SVRA 6
- Target Price
- SD N/A
- SVRA $8.83
- AVG Volume (30 Days)
- SD 303.1K
- SVRA 874.5K
- Earning Date
- SD 03-10-2025
- SVRA 05-08-2025
- Dividend Yield
- SD 3.80%
- SVRA N/A
- EPS Growth
- SD 3.05
- SVRA N/A
- EPS
- SD 1.69
- SVRA N/A
- Revenue
- SD $125,290,000.00
- SVRA N/A
- Revenue This Year
- SD $57.83
- SVRA N/A
- Revenue Next Year
- SD N/A
- SVRA N/A
- P/E Ratio
- SD $6.86
- SVRA N/A
- Revenue Growth
- SD N/A
- SVRA N/A
- 52 Week Low
- SD $10.31
- SVRA $2.26
- 52 Week High
- SD $15.31
- SVRA $5.34
- Technical
- Relative Strength Index (RSI)
- SD 49.53
- SVRA 46.86
- Support Level
- SD $10.74
- SVRA $2.43
- Resistance Level
- SD $11.50
- SVRA $2.72
- Average True Range (ATR)
- SD 0.41
- SVRA 0.16
- MACD
- SD -0.04
- SVRA 0.02
- Stochastic Oscillator
- SD 48.93
- SVRA 72.63
About SD SandRidge Energy Inc.
SandRidge Energy Inc is a United States-based oil and natural gas company. It is engaged in the exploration, development, and production of crude oil, natural gas, and Natural gas liquids. Business activities of the group include Exploration and Production, Drilling and Oil Field Services, and Midstream Gas Services.
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.